o-Touch” Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode for Small Hepatocellular Carcinoma (= 3cm): A Prospective multicenter Study

Seoul National University Hospital0 个研究点目标入组 159 人开始时间: 待定最近更新: 2024年8月19日

适应症

试验速览

Final Enrollment Number: 159 Participants:158 Dropped: 6 2. Efficacy: (Local recurrence rates 12 months after treatment ) 3. Adverse Event :2022-11-21 Radio-Frequency Ablation -> 2022.11.23 RUQ pain ->22.11.24 yellowish sputum ->PCD insertion (2022.11.28) : PI determined that this was a complication of RFA. 4. Brief Summary Efficacy (Local recurrence rates 12 months after treatment ) Seoul National University Hospital : 0.77 % (2/259) Samsung Medical Center Hospita: 1.74% (4/230) Chosun University Hospita: 2.74% (2/73)

•(1) Patients who agreed to the protocol requirements and submitted consent
•(2) 20 years old-85 years old
•(3) Child-Pugh Class A or B7
•(4) Among patients with cirrhosis, patients suspected of having HCC of 1-3 cm in size on MDCT or MRI performed within 60 days, and are going to undergo RFA

•(1) When the number of malignant liver tumors is 2 or more
•(2) When the maximum size of the tumor exceeds 3 cm (diffuse carcinoma)
•(3) Patients with previous medical history of liver cancer who have recurrent liver cancer within 2 years
•(4) When the tumor adheres to the portal vein or hepatic vein of 5 mm or larger
•(5) When the tumor is not visible even under CEUS-fusion image guidance
•(6) severe liver failure (Child-Pugh class B8, B9 or C)
•(7) In case of invasion of hepatic vessels by HCC
•(8) Severe coagulopathy (if platelet is below 50,000/mm3, INR is over 50% prolongation)
•(9) When there is metastasis outside the liver
•(10) A situation where the probability of obtaining appropriate data suitable for the research purpose is very low

发起方